Our Website Uses Cookies 


We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.


For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Morag Peberdy drafts a range of intellectual property agreements including research and collaboration agreements, patent licences, intellectual property pipeline arrangements, joint ventures, and other IP-related agreements, particularly in the life sciences sector. Ms. Peberdy advises clients on the intellectual property issues arising in corporate transactions, including mergers and acquisitions, initial public offerings, venture capital investments, royalty monetizations and restructurings. Ms. Peberdy has a background in biological sciences and she particularly enjoys working with clients in the life science sector.

  • Crescendo Biologics Ltd in an exclusive, worldwide licensing agreement with Zai Lab Limited, under which Zai Lab will develop, commercialize, and manufacture a topical, innovative antibody VH domain therapeutic for potential application in inflammatory indications.
  • Ziylo Ltd on its sale to Novo Nordisk for a total consideration that may exceed $800 million, the formation of Carbometrics Limited to which Ziylo spun-out certain assets, a research agreement between Carbometrics and Ziylo, and the grant of an exclusive license to develop applications in diagnostics and continuous glucose monitoring.
  • Abingworth on its £13 million Series ‘A’ investment in Virion Biotherapeutics Limited, a biotechnology company developing novel therapeutics for respiratory viral infections, and subsequently advising Virion on its commercial agreements.
  • AstraZeneca on its acquisition of Takeda’s respiratory business, and on its divestment of various product portfolios, including Rhinocort Aqua to Cilag.
  • LifeArc (formerly MRC Technology), a UK-based medical research charity, in the monetization of a portion of its royalties relating to Keytruda® for $1.297 billion (approximately £1 billion), the largest single-product royalty monetization ever done by a non-profit.
  • Laboratorios Esteve, S.A. in a global multi-programme discovery and development collaboration with Mundipharma Laboratories GmbH and Purdue Pharmaceuticals LP to bring to market important next generation products for the management of pain.   
  • The Walter and Eliza Hall Institute of Medical Research, Australia’s oldest medical research institute, in its monetization of a portion of its royalty interests in Venetoclax for up to U.S. $325 million (A$406 million), consisting of an up-front payment of US$250 million and up to US$75 million of additional payments upon the attainment of certain milestones, the largest royalty monetization by a non-profit institution outside the United States.
  • A UK life science plc on a China-specific out-licence of its key products in development.
  • A luxury goods company on trademark and copyright litigation in the UK and Belgium.
  • Cambridge Antibody Technology in its successful English court litigation over royalties in relation to sales of the monoclonal antibody product Humira.
  • Securing the in-licensing of patent and know-how rights to two UK spin-out companies in the fields of rheumatology, and anti-inflammatory and anti-cancer therapy.
  • A large U.S. pharmaceutical company in a English court action involving a patent license agreement relating to antibody technology.
  • Advising on IP diligence, reps and warranties, and preparing IP agreements for a complex medical device M&A transaction.  
  • Multi-jurisdictional trade mark licensing for an international consumer goods company.
  • The interpretation of patent licence and R & D agreements relating to various life science technologies for a major UK research body.    
  • A UK listed technology company in a complex English patent entitlement and breach of confidence action.
  • Intercell AG in connection with its acquisition of Cytos Biotechnology Ltd’s platform technology for monoclonal antibody discovery.   
  • The intellectual property aspects of a U.S. listed company's potential hostile bid for a listed life sciences company.

Pro Bono

  • Chair of pro bono activities in the London office.
  • Barnardo’s (the UK’s leading children’s charity) on a range of intellectual property issues.
  • An individual client, referred by LawWorks, to successfully resolve a UK copyright action.

Memberships and Affiliations

  • Member of the Consultation Board, PLC Life Sciences Service
  • UK BioIndustry Association Intellectual Property Advisory Committee
  • Licensing Executive Society (LES)
  • International Association for the Protection of Intellectual Property (AIPPI)
  • The Intellectual Property Lawyers Organisation (TIPLO)
  • Euromoney Legal Media Group, Europe Women in Business Law Awards - Winner for Patent (2015-2016); shortlisted for Patent (2017-2018)
  • IAM Patent 1000 - The World’s Leading Patent Practitioners, Recommended (2014-2019)   
  • Legal 500 UK
    • Pharmaceuticals & Biotech (2012-2016)
    • IP (2011-2013)